TARSUS PHARMACEUTICALS, INC. (TARS) Quick Ratio
- Quick ratio · latest quarter: Value 3.11×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.11× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $545.72M ÷ $175.75M ≈ 3.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 545.72M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 175.75M USD | Liabilities, Current |
| Cash and equivalents | 204.59M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 245.09M USD | Marketable Securities, Current |
| Customer receivables | 96.03M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 4.38M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $545.72M | $175.75M | $204.59M | $245.09M | $96.03M | $4.38M | 3.11× |
| 2026-03-31 | $489.08M | $143.51M | $102.19M | $286.54M | $100.34M | $4.57M | 3.41× |
| 2025-12-31 | $502.32M | $135.69M | $183.64M | $233.63M | $85.06M | $4.37M | 3.70× |
| 2025-09-30 | $474.46M | $117.05M | $112.72M | $289.11M | $72.62M | $3.84M | 4.05× |
| 2025-06-30 | $439.48M | $90.25M | $96.65M | $284.50M | $58.33M | $3.87M | 4.87× |
| 2025-03-31 | $470.34M | $86.31M | $175.79M | $232.13M | $62.43M | $2.71M | 5.45× |
| 2024-12-31 | $338.13M | $80.61M | $94.82M | $196.56M | $46.76M | $2.62M | 4.19× |
| 2024-09-30 | $346.11M | $65.87M | $176.21M | $140.74M | $29.16M | $2.85M | 5.25× |
| 2024-06-30 | $353.11M | $51.57M | $181.09M | $142.49M | $29.53M | $2.19M | 6.85× |
| 2024-03-31 | $328.41M | $42.53M | $193.71M | $104.82M | $29.89M | $4.04M | 7.72× |
| 2023-12-31 | $244.06M | $36.94M | $224.95M | $2.50M | $16.62M | $3.11M | 6.61× |
| 2023-09-30 | $252.25M | $23.25M | $226.67M | $20.21M | $5.36M | $15.00K | 10.85× |
| 2023-06-30 | (m) | $14.77M | $106.77M | $71.45M | (m) | (m) | (m) |
| 2023-03-31 | $203.72M | $13.26M | $66.00M | $135.22M | $2.50M | (m) | 15.37× |
| 2022-12-31 | (m) | $15.43M | $71.66M | $145.37M | (m) | (m) | (m) |
| 2022-09-30 | $226.59M | $14.27M | $169.49M | $57.08M | $17.00K | (m) | 15.88× |
| 2022-06-30 | $245.38M | $11.72M | $245.36M | $0.00 | $17.00K | (m) | 20.94× |
| 2022-03-31 | $175.32M | $12.61M | $175.01M | $291.00K | $17.00K | (m) | 13.90× |
| 2021-12-31 | (m) | $11.48M | $171.33M | $483.00K | (m) | (m) | (m) |
| 2021-09-30 | (m) | $10.37M | $183.80M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $10.46M | $176.74M | (m) | $20.00M | (m) | (m) |
| 2021-03-31 | (m) | $10.12M | $156.18M | (m) | $25.00M | (m) | (m) |
| 2020-12-31 | (m) | $5.39M | $168.13M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.14M | $86.33M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $53.13M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $55.89M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $819.00K | $57.95M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $337.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |